When palliative care is delivered via telehealth, there are a number of advantages. They can be at home, in their pajamas, ...

At ASCO, Astra Zeneca reported that its drug Enhertu stalled the growth of tumors by more than a year in women with the most ...

The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago — is ...

The first patients to receive Intellia's CRISPR-based therapy for hereditary angioedema saw their swelling attacks virtually ...

AstraZeneca is having another big ASCO, but the art of comfort care for cancer patients also got a plenary session.

The body mass index has long been slammed as a blunt instrument for evaluating health, even more so with new obesity drugs changing the conversation about weight and well-being. Now a study reasserts ...

AstraZeneca reports at ASCO that its drug Tagrisso slowed down lung cancer progression for a median of several years in stage ...

Recap: Today's top stories from ASCO 2024 include updates on safety data about a myelofibrosis candidate, and record ...

At an ASCO 2024 event, Richard Pazdur, the FDA's top oncologist, said the agency wants to see companies conducting studies ...

The Biden administration has significantly opened the door to drug treatment strategies that help reduce substance use, even ...

The effectiveness and safety of MDMA-assisted therapy for post-traumatic stress disorder will be scrutinized soon by FDA ...

At a STAT event, oncology leaders spoke of advances that are turning old ideas like antibody-drug conjugates into broadly ...